
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about the contents of this circular, you should consult your stockbroker or other registered securities dealer, bank manager, solicitor, accountant or other professional adviser immediately.

If you have sold or transferred your shares in Shenzhen Hepalink Pharmaceutical Group Co., Ltd., you should nevertheless immediately inform the person to whom you sold or transferred the shares of the contents of this circular, so that they can take appropriate action.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



()
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

**2022 WORK REPORT OF THE BOARD OF DIRECTORS
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE
2022 ANNUAL REPORT AND ITS SUMMARY,
H SHARES RESULTS ANNOUNCEMENT,
H SHARES 2022 ANNUAL REPORT, 2022 CORPORATE GOVERNANCE REPORT AND
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2022 FINAL FINANCIAL REPORT
2022 PROFIT DISTRIBUTION PROPOSAL
RE-APPOINTMENT OF AUDITORS OF THE COMPANY
ELECTION OF THE SIXTH SESSION OF THE BOARD
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF
THE SIXTH SESSION OF THE BOARD
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT
USING INTERNAL FUNDS
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2023
AMENDMENT OF ARTICLES OF ASSOCIATION
AND
NOTICE OF THE 2022 ANNUAL GENERAL MEETING**

Appendix A to the circular, dated 30 November 2022, is available on the website of the AGM (AGM AGM) at 3031, 2:30, () on 22, 2023. The AGM will be held on 2/12/2023 at 10:00 AM.

Appendix B to the circular, dated 30 November 2022, is available on the website of the AGM (AGM AGM) at 3031, 2:30, () on 22, 2023. The AGM will be held on 2/12/2023 at 10:00 AM.

Appendix C to the circular, dated 30 November 2022, is available on the website of the AGM (AGM AGM) at 3031, 2:30, () on 22, 2023. The AGM will be held on 2/12/2023 at 10:00 AM.

Appendix D to the circular, dated 30 November 2022, is available on the website of the AGM (AGM AGM) at 3031, 2:30, () on 22, 2023. The AGM will be held on 2/12/2023 at 10:00 AM.

CONTENTS

	<i>P</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
1.	4
2.	4
2022	4
2022	5
2022 A	5
2022	5
2022	6
2022	6
2022	7
2022	7
2022	9
2022	9
2022	9
3. A	9
4. <input checked="" type="checkbox"/>	10
5.	11
APPENDIX I – PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD ...	12
APPENDIX II – AMENDMENT OF ARTICLES OF ASSOCIATION	18
NOTICE OF THE 2022 ANNUAL GENERAL MEETING	20
<i>Note: ...</i>	

DEFINITIONS

I am not a mathematician, and I do not know what I am doing. I am only a student of the art of the possible.

□ A

LETTER FROM THE BOARD



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

Executive Director:
(C. J. B.)
(D. G. M.)
(G. M.)

Independent Director:
.....
.....
.....

..... P. C:
..... 21
.....
.....

.....
..... H. K.
..... 4724, 471
..... K.
..... 30
..... K.

A, 20, 2023

- 2022 WORK REPORT OF THE BOARD OF DIRECTORS
- 2022 WORK REPORT OF THE SUPERVISORY COMMITTEE
- 2022 ANNUAL REPORT AND ITS SUMMARY,
- H SHARES RESULTS ANNOUNCEMENT,
- H SHARES 2022 ANNUAL REPORT,
- 2022 CORPORATE GOVERNANCE REPORT AND
- 2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
- 2022 FINAL FINANCIAL REPORT
- 2022 PROFIT DISTRIBUTION PROPOSAL
- RE-APPOINTMENT OF AUDITORS OF THE COMPANY
- ELECTION OF THE SIXTH SESSION OF THE BOARD
- REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF
- THE SIXTH SESSION OF THE BOARD
- ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE
- PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND
- CASH FLOW MANAGEMENT
- USING INTERNAL FUNDS
- APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO
- CERTAIN BANKS FOR 2023
- AMENDMENT OF ARTICLES OF ASSOCIATION

LETTER FROM THE BOARD

1. INTRODUCTION

The Board of Directors (the Board) of the Company is pleased to present to you the 2022 Annual Report. The Board is committed to providing you with the information you need to make informed decisions about the Company. The Board is also committed to providing you with the information you need to make informed decisions about the Company.

The Board is pleased to present to you the 2022 Annual Report. The Board is committed to providing you with the information you need to make informed decisions about the Company. The Board is also committed to providing you with the information you need to make informed decisions about the Company.

- (1) The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (2) The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (3) The 2022 Annual Report, including the financial statements, is available on the Company's website. The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (4) The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (5) The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (6) The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (7) The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (8) The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (9) The 2022 Annual Report, including the financial statements, is available on the Company's website.

The Board is pleased to present to you the 2022 Annual Report. The Board is committed to providing you with the information you need to make informed decisions about the Company. The Board is also committed to providing you with the information you need to make informed decisions about the Company.

- (10) The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (11) The 2022 Annual Report, including the financial statements, is available on the Company's website.
- (12) The 2022 Annual Report, including the financial statements, is available on the Company's website.

2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

i. 2022 Work Report of the Board of Directors

The Board of Directors is pleased to present to you the 2022 Annual Report. The Board is committed to providing you with the information you need to make informed decisions about the Company. The Board is also committed to providing you with the information you need to make informed decisions about the Company.

The Board of Directors is pleased to present to you the 2022 Annual Report. The Board is committed to providing you with the information you need to make informed decisions about the Company. The Board is also committed to providing you with the information you need to make informed decisions about the Company.

LETTER FROM THE BOARD

ii. 2022 Work Report of the Supervisory Committee

The Supervisory Committee has reviewed the 2022 Work Report of the Supervisory Committee, which was approved by the Board of Directors on March 29, 2023. The Supervisory Committee has also reviewed the 2022 Work Report of the Management, which was approved by the Board of Directors on March 29, 2023. The Supervisory Committee has also reviewed the 2022 Work Report of the Board of Directors, which was approved by the Board of Directors on March 29, 2023.

iii. 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report

The Board of Directors has reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report. The Board of Directors has also reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report. The Board of Directors has also reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report.

iv. 2022 Final Financial Report

The Board of Directors has reviewed the 2022 Final Financial Report, which was approved by the Board of Directors on March 29, 2023. The Board of Directors has also reviewed the 2022 Final Financial Report, which was approved by the Board of Directors on March 29, 2023. The Board of Directors has also reviewed the 2022 Final Financial Report, which was approved by the Board of Directors on March 29, 2023.

v. 2022 Profit Distribution Proposal

The Board of Directors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on March 29, 2023. The Board of Directors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on March 29, 2023. The Board of Directors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on March 29, 2023.

The Board of Directors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on March 29, 2023. The Board of Directors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on March 29, 2023. The Board of Directors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on March 29, 2023.

LETTER FROM THE BOARD

vi. Re-appointment of auditors of the Company

The Board of Directors of the Company, at its meeting held on 29, 2023, has resolved to re-appoint PricewaterhouseCoopers & Co., Chartered Accountants, as the auditors of the Company for the financial year ending 31, 2023.

The Board of Directors of the Company, at its meeting held on 29, 2023, has resolved to re-appoint A. P. & Co., Chartered Accountants, as the auditors of the Company for the financial year ending 31, 2023.

vii. Election of the sixth session of the Board

The Board of Directors of the Company, at its meeting held on 29, 2023, has resolved to elect the following members to the sixth session of the Board of Directors of the Company: **Mr. Li**, **Ms. Li**, **Mr. Shan**, **Dr. Lu**, **Mr. Zhang**, **Mr. Huang** and **Mr. Yi**.

LETTER FROM THE BOARD

The Board has reviewed the financial statements of the Company for the year ended 31 December 2014, and has approved the financial statements for publication and distribution to the shareholders of the Company.

At the meeting of the Board of Directors held on 14 January 2015, the Board has approved the financial statements of the Company for the year ended 31 December 2014, and has approved the financial statements for publication and distribution to the shareholders of the Company. The Board has also approved the dividend for the year ended 31 December 2014, which is a final dividend of 100,000 Hong Kong dollars (HK\$100,000) per share. The Board has also approved the appointment of Mr. Zheng and Ms. Tang as independent non-executive directors of the Board for the sixth session of the Board. The Board has also approved the election of Mr. Zheng and Ms. Tang as members of the Supervisory Committee for the sixth session of the Supervisory Committee.

A copy of the financial statements of the Company for the year ended 31 December 2014, together with a copy of the dividend, is being sent to the shareholders of the Company.

viii. Remuneration of independent non-executive Directors of the sixth session of the Board

The remuneration of independent non-executive directors of the sixth session of the Board is as follows: Mr. Zheng, HK\$100,000 per annum (including a fee of HK\$10,000 per annum), and Ms. Tang, HK\$100,000 per annum (including a fee of HK\$10,000 per annum). The remuneration of independent non-executive directors of the sixth session of the Board is subject to the approval of the shareholders of the Company at the general meeting.

ix. Election of the sixth session of the Supervisory Committee

At the meeting of the Board of Directors held on 18 January 2015, the Board has approved the election of Mr. Zheng and Ms. Tang as independent non-executive directors of the Board for the sixth session of the Board. The Board has also approved the election of Mr. Zheng and Ms. Tang as members of the Supervisory Committee for the sixth session of the Supervisory Committee. The Board has also approved the appointment of Mr. Zheng and Ms. Tang as independent non-executive directors of the Board for the sixth session of the Board.

LETTER FROM THE BOARD

敬啟者，茲將本會最近選舉之結果公佈如下：

第一屆理事會成員 (鄭澤輝)，任期 53 個月，自 2006 年 1 月 1 日起生效。該會成員包括：主席 1 名、副主席 2 名、秘書長 1 名、副秘書長 2 名、財政 1 名、副財政 2 名、審核委員會主席 1 名、副審核委員會主席 2 名、及審核委員會成員 4 名。該會成員之任期將於 2011 年 12 月 31 日屆滿。

敬啟者，茲將本會最近選舉之結果公佈如下：

第二屆理事會成員 (唐海均)，任期 44 個月，自 2001 年 1 月 1 日起生效。該會成員包括：主席 1 名、副主席 2 名、秘書長 1 名、副秘書長 2 名、財政 1 名、副財政 2 名、審核委員會主席 1 名、副審核委員會主席 2 名、及審核委員會成員 4 名。該會成員之任期將於 2014 年 12 月 31 日屆滿。

本會之宗旨為推廣及發展中國會計師公會之專業服務，並促進會員之福利。本會之業務範圍包括：提供專業會計服務、提供專業培訓、提供專業諮詢、提供專業研究、提供專業出版、提供專業展覽、提供專業會議、提供專業旅遊、提供專業康樂、提供專業體育、提供專業文化、提供專業藝術、提供專業音樂、提供專業舞蹈、提供專業戲劇、提供專業電影、提供專業電視、提供專業廣播、提供專業出版、提供專業展覽、提供專業會議、提供專業旅遊、提供專業康樂、提供專業體育、提供專業文化、提供專業藝術、提供專業音樂、提供專業舞蹈、提供專業戲劇、提供專業電影、提供專業電視、提供專業廣播。

本會之宗旨為推廣及發展中國會計師公會之專業服務，並促進會員之福利。本會之業務範圍包括：提供專業會計服務、提供專業培訓、提供專業諮詢、提供專業研究、提供專業出版、提供專業展覽、提供專業會議、提供專業旅遊、提供專業康樂、提供專業體育、提供專業文化、提供專業藝術、提供專業音樂、提供專業舞蹈、提供專業戲劇、提供專業電影、提供專業電視、提供專業廣播。

本會之宗旨為推廣及發展中國會計師公會之專業服務，並促進會員之福利。本會之業務範圍包括：提供專業會計服務、提供專業培訓、提供專業諮詢、提供專業研究、提供專業出版、提供專業展覽、提供專業會議、提供專業旅遊、提供專業康樂、提供專業體育、提供專業文化、提供專業藝術、提供專業音樂、提供專業舞蹈、提供專業戲劇、提供專業電影、提供專業電視、提供專業廣播。

本會之宗旨為推廣及發展中國會計師公會之專業服務，並促進會員之福利。本會之業務範圍包括：提供專業會計服務、提供專業培訓、提供專業諮詢、提供專業研究、提供專業出版、提供專業展覽、提供專業會議、提供專業旅遊、提供專業康樂、提供專業體育、提供專業文化、提供專業藝術、提供專業音樂、提供專業舞蹈、提供專業戲劇、提供專業電影、提供專業電視、提供專業廣播。

本會之宗旨為推廣及發展中國會計師公會之專業服務，並促進會員之福利。本會之業務範圍包括：提供專業會計服務、提供專業培訓、提供專業諮詢、提供專業研究、提供專業出版、提供專業展覽、提供專業會議、提供專業旅遊、提供專業康樂、提供專業體育、提供專業文化、提供專業藝術、提供專業音樂、提供專業舞蹈、提供專業戲劇、提供專業電影、提供專業電視、提供專業廣播。

LETTER FROM THE BOARD

x. **Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds**

The Board of Directors of the Association, on May 29, 2023, approved the purchase of wealth management products and cash flow management using internal funds. The Board also approved the purchase of the following products:

On May 29, 2023, the Board of Directors of the Association approved the purchase of the following products:

xi. **Application for Credit Line and Providing Guarantee to Certain Banks for 2023**

The Board of Directors of the Association, on May 29, 2023, approved the application for a credit line and providing a guarantee to certain banks for 2023. The Board also approved the application for a credit line and providing a guarantee to certain banks for 2023.

On May 29, 2023, the Board of Directors of the Association approved the application for a credit line and providing a guarantee to certain banks for 2023.

xii. **Amendment of Articles of Association**

The Board of Directors of the Association, on May 29, 2023, approved the amendment of the Articles of Association. The Board also approved the amendment of the Articles of Association.

On May 29, 2023, the Board of Directors of the Association approved the amendment of the Articles of Association.

3. ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES

The Board of Directors of the Association, on May 29, 2023, approved the annual general meeting and the closure of the register of members of H shares. The Board also approved the annual general meeting and the closure of the register of members of H shares.

LETTER FROM THE BOARD

The Board of Directors of the Association of...

On 17, 2023... 22, 2023 (...

On 29, 2023... 31, 2023,...

4. VOTING BY POLL

13.39(4)...

On 24...

LETTER FROM THE BOARD

5. RECOMMENDATION

..... A

.....
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li

C.

Appendix I: Profiles of the Proposed Sixth Session of the Board

Non-independent Directors**(i) Mr. Li Li**

(李鋌), 1959, male, Chinese, Bachelor's degree, currently a senior executive of the company. He has been a director of the company since 2012. He has extensive experience in the field of business management and has served in various positions of responsibility in the company. He is also a member of the company's board of directors and has participated in the company's strategic planning and decision-making. He has a strong background in finance and accounting, and has been instrumental in the company's financial management and reporting. He is a dedicated professional who is committed to the company's success and the interests of its shareholders.

(ii) Ms. Li Tan

(李坦), le 58, ...

A, 1998. ... 2007; ... 2014; ... 2010; ... 2013; ... 2015; ... 2016.

... 1987 ... 2005.

A ... 922,391,179 A ... 73.96% ... 408,041,280 A ... 99.00% ... 1.00% ... 474,029,899 A ... 99.00% ... 1.00% ... 40,320,000 A ...

(iii) Mr. Shan Yu

Mr. Shan Yu (單宇), born in 1962, is a Chinese national and holds a Bachelor's degree in Business Administration from the University of Shanghai for Science and Technology. He has worked in various capacities in the financial industry, including as a senior manager in a major bank and as a senior advisor to the government. He has also been involved in several public service projects and is currently a member of the Shanghai Municipal People's Congress.

Mr. Shan Yu has held several key positions in the financial sector. He served as the Deputy Chairman of the Shanghai Municipal Finance and Credit Association from 1998 to 2000. He was also the Chairman of the Shanghai Municipal Finance and Credit Association from 2000 to 2007. In 2009, he was appointed as the Chairman of the Shanghai Municipal Finance and Credit Association. He has also served as the Chairman of the Shanghai Municipal Finance and Credit Association from 2010 to 2013. He is currently the Chairman of the Shanghai Municipal Finance and Credit Association, A, since 2014.

Mr. Shan Yu has also held several key positions in the financial sector. He served as the Deputy Chairman of the Shanghai Municipal Finance and Credit Association from 1982 to 2005.

Mr. Shan Yu has a strong track record in the financial industry. He has been involved in several major financial projects, including the establishment of the Shanghai Municipal Finance and Credit Association. He has also been involved in several public service projects and is currently a member of the Shanghai Municipal People's Congress. He has a net worth of approximately 46,425,600 A, and he has a net worth of approximately 15,118,035 A. He has a net worth of approximately 52,302,892 A, and he has a net worth of approximately 3.56%.

(iv) Mr. Zhang Ping

Mr. Zhang Ping (張平), born in 1958, is a Chinese national and holds a Bachelor's degree in Business Administration from the University of Shanghai for Science and Technology. He has worked in various capacities in the financial industry, including as a senior manager in a major bank and as a senior advisor to the government. He has also been involved in several public service projects and is currently a member of the Shanghai Municipal People's Congress.

Mr. Zhang Ping has held several key positions in the financial sector. He served as the Deputy Chairman of the Shanghai Municipal Finance and Credit Association from 2002 to 2021. He was also the Chairman of the Shanghai Municipal Finance and Credit Association from 2021 to 2022. He is currently the Chairman of the Shanghai Municipal Finance and Credit Association, A, since 2022. He has also served as the Chairman of the Shanghai Municipal Finance and Credit Association from 1988 to 2002.

Mr. Zhang Ping has a strong track record in the financial industry. He has been involved in several major financial projects, including the establishment of the Shanghai Municipal Finance and Credit Association. He has also been involved in several public service projects and is currently a member of the Shanghai Municipal People's Congress. He has a net worth of approximately 46,425,600 A, and he has a net worth of approximately 15,118,035 A. He has a net worth of approximately 52,302,892 A, and he has a net worth of approximately 3.56%.

At the end of the year, the company's net profit attributable to equity holders of the parent company was RMB1,012.4 million, an increase of 10.2% over the corresponding period of the previous year. The company's operating profit was RMB1,012.4 million, an increase of 10.2% over the corresponding period of the previous year. The company's operating profit margin was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's net profit margin was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's return on equity was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's return on assets was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's operating profit margin was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's net profit margin was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's return on equity was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's return on assets was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year.

At the end of the year, the company's net profit attributable to equity holders of the parent company was RMB1,012.4 million, an increase of 10.2% over the corresponding period of the previous year. The company's operating profit was RMB1,012.4 million, an increase of 10.2% over the corresponding period of the previous year. The company's operating profit margin was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's net profit margin was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's return on equity was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year. The company's return on assets was 10.2%, an increase of 0.1 percentage points over the corresponding period of the previous year.

Independent Non-Executive Directors

(v) Dr. Lu Chuan

Dr. Lu Chuan (吕川), born in 1953, is a senior executive with extensive experience in the pharmaceutical industry. He has held various senior positions in major pharmaceutical companies in China and abroad. He is currently an independent non-executive director of the company. He has been a member of the board since 2019. He is also a member of the board of directors of the company since 2019.

Dr. Lu Chuan has a long career in the pharmaceutical industry. He joined the company in 1991. He held various positions in the company, including General Manager, Deputy General Manager, and Chairman. He has extensive experience in the pharmaceutical industry. He has been a member of the board since 2019. He is also a member of the board of directors of the company since 2019. He has a doctorate degree in medicine. He is also a member of the board of directors of the company since 2019. He is also a member of the board of directors of the company since 2019. He has a doctorate degree in medicine. He is also a member of the board of directors of the company since 2019. He is also a member of the board of directors of the company since 2019.

Dr. Lu Chuan has a long career in the pharmaceutical industry. He joined the company in 1991. He held various positions in the company, including General Manager, Deputy General Manager, and Chairman. He has extensive experience in the pharmaceutical industry. He has been a member of the board since 2019. He is also a member of the board of directors of the company since 2019. He has a doctorate degree in medicine. He is also a member of the board of directors of the company since 2019. He is also a member of the board of directors of the company since 2019.

A

(vi) Mr. Huang Peng

(黃鵬), 74, 1949, 2003. 1995 1985. 1988, (新時代企業家研究院) (. 601890), (. 301180), (. 300819) & (. 603828).

. A A

A

(vii) Mr. Yi Ming

(易銘), 46, 1977, 2002 A 2014. (.) A 2003 2012. (A) A 2013 2018. A A 2018.

. A A

A

Article 14. The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any promissory notes, mortgages, deeds, contracts, leases, and other instruments, and to incur any debt, liability, or obligation of the Association, and to execute any documents and to take any action necessary to carry out the powers granted to it by the Articles of Association and the Bylaws of the Association.

Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
<p>Article 14 The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any promissory notes, mortgages, deeds, contracts, leases, and other instruments, and to incur any debt, liability, or obligation of the Association, and to execute any documents and to take any action necessary to carry out the powers granted to it by the Articles of Association and the Bylaws of the Association.</p>	<p>Article 14 The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any promissory notes, mortgages, deeds, contracts, leases, and other instruments, and to incur any debt, liability, or obligation of the Association, and to execute any documents and to take any action necessary to carry out the powers granted to it by the Articles of Association and the Bylaws of the Association.</p>
<p>Article 97 A resolution of the Board of Directors shall be effective if approved by a majority of the members of the Board of Directors. A resolution of the Board of Directors shall be effective if approved by a majority of the members of the Board of Directors.</p>	<p>Article 97 A resolution of the Board of Directors shall be effective if approved by a majority of the members of the Board of Directors. A resolution of the Board of Directors shall be effective if approved by a majority of the members of the Board of Directors.</p>

Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
<p>Article 148. The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p> <p>Article 149. The Board of Directors shall have the authority to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p>	<p>Article 148. The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p> <p>Article 149. The Board of Directors shall have the authority to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p>
<p>Article 150 The Board of Directors shall have the authority to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p>	<p>Article 150 The Board of Directors shall have the authority to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p>
<p>Article 156 The Board of Directors shall have the authority to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p>	<p>Article 156 The Board of Directors shall have the authority to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p>
<p>Article 158 The Board of Directors shall have the authority to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p>	<p>Article 158 The Board of Directors shall have the authority to execute any promissory notes, mortgages, deeds, contracts, and other instruments, and to execute any other documents that may be necessary or appropriate in the course of its business.</p>

NOTICE OF THE 2022 A

NOTICE IS HEREBY GIVEN 2022

Company

ORDINARY RESOLUTIONS

SPECIAL RESOLUTIONS 深圳市海

NOTICE OF THE 2022 ANNUAL GENERAL MEETING

ORDINARY RESOLUTION

8. The directors, the company secretary and the auditors to be appointed to the office of directors, company secretary and auditors for the year ending 31 December 2022;

SPECIAL RESOLUTION

9. The directors, the company secretary and the auditors to be appointed to the office of directors, company secretary and auditors for the year ending 31 December 2022;

ORDINARY RESOLUTIONS

10. The directors, the company secretary and the auditors to be appointed to the office of directors, company secretary and auditors for the year ending 31 December 2022;
11. The directors, the company secretary and the auditors to be appointed to the office of directors, company secretary and auditors for the year ending 31 December 2022:
- 11.01 The directors, the company secretary and the auditors to be appointed to the office of directors, company secretary and auditors for the year ending 31 December 2022;
 - 11.02 The directors, the company secretary and the auditors to be appointed to the office of directors, company secretary and auditors for the year ending 31 December 2022;
 - 11.03 The directors, the company secretary and the auditors to be appointed to the office of directors, company secretary and auditors for the year ending 31 December 2022;
 - 11.04 The directors, the company secretary and the auditors to be appointed to the office of directors, company secretary and auditors for the year ending 31 December 2022;

NOTICE OF THE 2022 ANNUAL GENERAL MEETING

12. *Resolution on the Report of the Board of Directors of the Company for the Year 2022:*
- 12.01 *Resolution on the Report of the Board of Directors of the Company for the Year 2022:*
- 12.02 *Resolution on the Report of the Board of Directors of the Company for the Year 2022:*
- 12.03 *Resolution on the Report of the Board of Directors of the Company for the Year 2022:*
13. *Resolution on the Report of the Board of Directors of the Company for the Year 2022:*
- 13.01 *Resolution on the Report of the Board of Directors of the Company for the Year 2022:*
- 13.02 *Resolution on the Report of the Board of Directors of the Company for the Year 2022:*

Li Li
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Li Li
A, | 20, 2023

NOTICE OF THE 2022 ANNUAL GENERAL MEETING

Notice:

- 1. The meeting will be held on Monday, 17, 2023 at 11:30 AM to 12:30 PM (online mode), at the Corporate Office of the Company, 17th Floor, The Park Hotel, 17/1, Park Road, Bangalore, 16/11/2023, at 4:30 PM on 16, 2023.
- 2. The meeting will be held on Monday, 17, 2023 at 11:30 AM to 12:30 PM (online mode), at the Corporate Office of the Company, 17th Floor, The Park Hotel, 17/1, Park Road, Bangalore, 16/11/2023, at 4:30 PM on 16, 2023.
- 3. The meeting will be held on Monday, 17, 2023 at 11:30 AM to 12:30 PM (online mode), at the Corporate Office of the Company, 17th Floor, The Park Hotel, 17/1, Park Road, Bangalore, 16/11/2023, at 4:30 PM on 16, 2023.
- 4. The meeting will be held on Monday, 17, 2023 at 11:30 AM to 12:30 PM (online mode), at the Corporate Office of the Company, 17th Floor, The Park Hotel, 17/1, Park Road, Bangalore, 16/11/2023, at 4:30 PM on 16, 2023.
- 5. The meeting will be held on Monday, 17, 2023 at 11:30 AM to 12:30 PM (online mode), at the Corporate Office of the Company, 17th Floor, The Park Hotel, 17/1, Park Road, Bangalore, 16/11/2023, at 4:30 PM on 16, 2023.
- 6. The meeting will be held on Monday, 17, 2023 at 11:30 AM to 12:30 PM (online mode), at the Corporate Office of the Company, 17th Floor, The Park Hotel, 17/1, Park Road, Bangalore, 16/11/2023, at 4:30 PM on 16, 2023.
- 7. The meeting will be held on Monday, 17, 2023 at 11:30 AM to 12:30 PM (online mode), at the Corporate Office of the Company, 17th Floor, The Park Hotel, 17/1, Park Road, Bangalore, 16/11/2023, at 4:30 PM on 16, 2023.
- 8. The meeting will be held on Monday, 17, 2023 at 11:30 AM to 12:30 PM (online mode), at the Corporate Office of the Company, 17th Floor, The Park Hotel, 17/1, Park Road, Bangalore, 16/11/2023, at 4:30 PM on 16, 2023.

